<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age>81</patient-age><report-id>JP-NOVOPROD-368904</report-id><gender>female</gender><reactions><reaction>Anti-insulin antibody positive</reaction><reaction>Haemoglobin A1C increased to 13.5%</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>NovoLin R CHU FlexPen</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>INSULIN GLULISINE</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Type 2 diabetes mellitus</indication></indications><patient-age>81</patient-age><outcomes><outcome>Required Inpatient Hospitalization</outcome></outcomes><country>Japan</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>170160_050</messagenumb>
		<messagesenderidentifier>NOVOPROD</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151548</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>JP-NOVOPROD-368904</safetyreportid>
		<primarysourcecountry>JP</primarysourcecountry>
		<occurcountry>JP</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-25</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2013-01-09</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-17</receiptdate>
		<additionaldocument>1</additionaldocument>
		<documentlist>E2b Differences Report</documentlist>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>JP-NOVOPROD-368904</companynumb>
		<primarysource>
			<reportercountry>JP</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
			<literaturereference>Tomomi Fujisawa, et.al. Effect of ciclosporin in an elderly patient with type 2 diabetes mellitus and positive anti-insulin antibodies test. The 49th Kinki Regional Meeting of the Japan Diabetes Society. 2012;p111</literaturereference>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVOPROD</senderorganization>
			<senderdepartment>Product Safety and Clinical Quality Assurance</senderdepartment>
			<sendergivename>Novo</sendergivename>
			<sendermiddlename>Nordisk</sendermiddlename>
			<senderfamilyname>Inc.</senderfamilyname>
			<senderstreetaddress>100 College Road West</senderstreetaddress>
			<sendercity>Princeton</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>08540</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>6099875831</sendertel>
			<sendertelcountrycode>1</sendertelcountrycode>
			<senderfax>6099878480</senderfax>
			<senderfaxcountrycode>1</senderfaxcountrycode>
			<senderemailaddress>NNPI_AE_REPORTING@NOVONORDISK.COM</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDAEDI.CDER</receiverdepartment>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3018276504</receivertel>
			<receivertelcountrycode>1</receivertelcountrycode>
			<receiveremailaddress>WTaylor@OC.FDA.GOV</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>PRIVACY</patientinitial>
			<patientonsetage>81</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientagegroup>6</patientagegroup>
			<patientsex code="2">Female</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Type 2 diabetes mellitus</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalcomment>duration not reported</patientmedicalcomment>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Anti-insulin antibody positive</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Anti-insulin antibody positive</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Anti-insulin antibody positive</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Haemoglobin A1C increased to 13.5%</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Haemoglobin A1C increased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Glycosylated haemoglobin increased</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<test>
				<testname>HbA1C</testname>
				<testresult>13.5</testresult>
				<testunit>%</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>HbA1C</testname>
				<testresult>12.5</testresult>
				<testunit>%</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>HbA1C</testname>
				<testresult>7.2</testresult>
				<testunit>%</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>NovoLin R CHU FlexPen</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb>UNKNOWN</drugbatchnumb>
				<drugauthorizationnumb>19-938</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Novo Nordisk A/S</drugauthorizationholder>
				<drugdosageform normalized="solution for injection">Solution for injection</drugdosageform>
				<drugadministrationroute code="058">Subcutaneous</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Type 2 diabetes mellitus</drugindication>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>INSULIN HUMAN</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>ZINC CHLORIDE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Anti-insulin antibody positive</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Reportable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Anti-insulin antibody positive</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Probable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glycosylated haemoglobin increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Reportable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glycosylated haemoglobin increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Probable</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>NovoLin R CHU FlexPen</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb>UNKNOWN</drugbatchnumb>
				<drugauthorizationnumb>19-938</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Novo Nordisk A/S</drugauthorizationholder>
				<drugdosageform normalized="solution for injection">Solution for injection</drugdosageform>
				<drugadministrationroute code="058">Subcutaneous</drugadministrationroute>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>INSULIN HUMAN</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>ZINC CHLORIDE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Anti-insulin antibody positive</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Reportable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Anti-insulin antibody positive</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Probable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glycosylated haemoglobin increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Reportable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glycosylated haemoglobin increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Probable</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>INSULIN GLULISINE</medicinalproduct>
				<drugadministrationroute code="058">Subcutaneous</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Type 2 diabetes mellitus</drugindication>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>INSULIN GLULISINE</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>This serious Literature case titled "Effect of cyclosporin in an <Semaphore x="2923190" class="MedDRA LLT" value="Elderly" score="1.00" ID="10014348">elderly </Semaphore>patient with <Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">type 2 diabetes mellitus </Semaphore>and <Semaphore x="2749660" class="MedDRA LLT" value="Antibody test positive" score="1.00" ID="10061427"><Semaphore x="2748230" class="MedDRA LLT" value="Anti-insulin antibody positive" score="1.00" ID="10053814">positive anti <Semaphore x="733661" class="Medicine" value="Insulin" score="1.00" ID="275827">insulin </Semaphore>antibodies </Semaphore>test</Semaphore>" referenced in " the 49th Kinki Regional Meeting of the Japan <Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">Diabetes </Semaphore>Society (Author: Tomomi Fujisawa, et.al)" and was reported by a <Semaphore x="2009300" class="Occupation" value="Health Care Professional" score="1.00" ID="C53287">health care professional </Semaphore>from Japan. It <Semaphore x="1805433" class="Procedure" value="Concern About Finances" score="1.00" ID="C104604">concerns </Semaphore>a 81-year old female patient with <Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">type II diabetes mellitus </Semaphore>treated with <Semaphore x="935646" class="Medicine" value="Novolin R" score="0.74" ID="297030">NovoLin R </Semaphore>Chu FlexPen (<Semaphore x="2949378" class="MedDRA LLT" value="Fasting" score="1.00" ID="10068315">fast </Semaphore>acting <Semaphore x="733661" class="Medicine" value="Insulin" score="1.00" ID="275827">Insulin </Semaphore>human) (as per the most sold list in Japan) on unknown dates and experienced "<Semaphore x="2014820" class="Disease or Finding" value="Hemoglobin Increased" score="1.00" ID="C78333"><Semaphore x="1989365" class="Procedure" value="Glycosylated Hemoglobin Measurement" score="1.00" ID="C64849">haemoglobin A1C </Semaphore>increased </Semaphore>to 13.5%" and "<Semaphore x="2748230" class="MedDRA LLT" value="Anti-insulin antibody positive" score="1.00" ID="10053814">anti <Semaphore x="733661" class="Medicine" value="Insulin" score="1.00" ID="275827">insulin </Semaphore>antibody positive</Semaphore>" beginning on an unknown date.Non Novo Nordisk suspect <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drug </Semaphore>included <Semaphore x="733661" class="Medicine" value="Insulin" score="1.00" ID="275827">Insulin </Semaphore>Glulisine on unknown dates due to <Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">type II diabetes mellitus</Semaphore>.Patient's height: not reported.Medical history includes <Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">type 2 diabetes mellitus </Semaphore>(duration not reported).The patient received <Semaphore x="733661" class="Medicine" value="Insulin" score="1.00" ID="275827">insulin </Semaphore><Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>for 7 years. The patient had adequate glycemic <Semaphore x="1854518" class="Disease or Finding" value="Disease Controlled" score="1.00" ID="C82500">control </Semaphore>with human <Semaphore x="733661" class="Medicine" value="Insulin" score="1.00" ID="275827">insulin </Semaphore>at 0.5 unit/weight (kg)/day until <Semaphore x="2981024" class="MedDRA LLT" value="Glycosylated haemoglobin increased" score="1.00" ID="10018484">HbA1c <Semaphore x="779631" class="Medicine" value="Level" score="0.49" ID="187620">level </Semaphore>increased </Semaphore>to 13.5% despite <Semaphore x="1863405" class="Procedure" value="Dose Increased" score="1.00" ID="C49503">increased dose </Semaphore>of human <Semaphore x="733661" class="Medicine" value="Insulin" score="1.00" ID="275827">insulin </Semaphore>to 1.2 U/weight kg/day, and she was referred to the reporting hospital. After <Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalization</Semaphore>, <Semaphore x="733661" class="Medicine" value="Insulin" score="1.00" ID="275827">insulin </Semaphore><Semaphore x="2419729" class="AnatomicStructure" value="Prepontine Cistern" score="1.00" ID="C33397">preparation </Semaphore>was switched to aspart 2.0 units/weight (kg) /day and was discharged from hospital with temporal improvement followed by deterioration.The patient repeated the same course but the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>was switched to Glulisine 2.8 units/ <Semaphore x="3320545" class="MedDRA LLT" value="Weight" score="1.00" ID="10047890">weight </Semaphore>(kg)/day in the second <Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalization</Semaphore>. Poor glycemic <Semaphore x="1854518" class="Disease or Finding" value="Disease Controlled" score="1.00" ID="C82500">control </Semaphore>persisted with HbA1c levels at 12.5% despite <Semaphore x="2809765" class="MedDRA LLT" value="Blood insulin increased" score="1.00" ID="10005614">high dose of <Semaphore x="733661" class="Medicine" value="Insulin" score="1.00" ID="275827">insulin </Semaphore></Semaphore>at 5.4 U/weight (kg)/day. Contribution of <Semaphore x="2748251" class="MedDRA LLT" value="Anti-insulin antibody" score="1.00" ID="10050692">anti <Semaphore x="733661" class="Medicine" value="Insulin" score="1.00" ID="275827">insulin </Semaphore>antibodies </Semaphore>was suspected and <Semaphore x="2048374" class="Procedure" value="Immunosuppressive Therapy" score="1.00" ID="C15261">immunosuppressive therapy </Semaphore>with cyclosporin was started. Subsequently, <Semaphore x="733661" class="Medicine" value="Insulin" score="1.00" ID="275827">insulin </Semaphore><Semaphore x="1863467" class="Procedure" value="Dose Reduced" score="1.00" ID="C49505">dose was reduced </Semaphore>rapidly. One year later, <Semaphore x="1608509" class="AnatomicStructure" value="Blood" score="1.00" ID="C12434">blood </Semaphore><Semaphore x="627832" class="Medicine" value="Glucose" score="0.49" ID="269493">glucose </Semaphore>was <Semaphore x="1854518" class="Disease or Finding" value="Disease Controlled" score="1.00" ID="C82500">controlled </Semaphore>with HbA1c of 7.2% with <Semaphore x="733661" class="Medicine" value="Insulin" score="1.00" ID="275827">insulin </Semaphore>dose at 0.9 unit/weight (kg)/day.Action taken to <Semaphore x="935646" class="Medicine" value="Novolin R" score="0.74" ID="297030">NovoLin R </Semaphore>Chu FlexPen was reported as product discontinued and the action taken to <Semaphore x="733661" class="Medicine" value="Insulin" score="1.00" ID="275827">Insulin </Semaphore>Glulisine was reported as Unknown.The overall <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>was recovered on an unknown date.Since last submission, the case was updated with the following:-Reporter causality changed to "probable"-<Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">Outcome </Semaphore>of events-Narrative updated accordingly.Comment: company comment: Human <Semaphore x="733661" class="Medicine" value="Insulin" score="1.00" ID="275827">insulin </Semaphore>is known to be antigenic, with low titres of antibodies developing in most patients (up to 80%). The effect of <Semaphore x="733661" class="Medicine" value="Insulin" score="1.00" ID="275827">insulin </Semaphore>antibodies on <Semaphore x="733661" class="Medicine" value="Insulin" score="1.00" ID="275827">insulin </Semaphore>pharmacokinetics, with the presence of binding <Semaphore x="2809177" class="MedDRA LLT" value="Blood immunoglobulin G" score="1.00" ID="10005593">IgG </Semaphore>in <Semaphore x="2507267" class="AnatomicStructure" value="Serum" score="1.00" ID="C13325">serum</Semaphore>, may delay time to peak levels of <Semaphore x="1882188" class="Disease or Finding" value="Empty Sella Syndrome" score="1.00" ID="C84686">free </Semaphore><Semaphore x="733661" class="Medicine" value="Insulin" score="1.00" ID="275827">insulin</Semaphore>. Antibodies may be cross reactive to both <Semaphore x="733661" class="Medicine" value="Insulin" score="1.00" ID="275827">insulin </Semaphore>aspart and human <Semaphore x="733661" class="Medicine" value="Insulin" score="1.00" ID="275827">insulin</Semaphore>.Becker KL: Principles and Practice of Endocrinology and <Semaphore x="2062233" class="Disease or Finding" value="Intermediary Metabolism Disorder" score="1.00" ID="C97091">Metabolism</Semaphore>, third edition 2001. and Lindholm A et. al. Immune <Semaphore x="1854566" class="Disease or Finding" value="Disease Response" score="1.00" ID="C50995">responses </Semaphore>to <Semaphore x="733661" class="Medicine" value="Insulin" score="1.00" ID="275827">insulin </Semaphore>aspart. <Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">Diabetes </Semaphore>Care 2002; 25: 876-82.</narrativeincludeclinical>
				<sendercomment>Human insulin is known to be antigenic, with low titres of antibodies developing in most patients (up to 80%). The effect of insulin antibodies on insulin pharmacokinetics, with the presence of binding IgG in serum, may delay time to peak levels of free insulin. Antibodies may be cross-reactive to both insulin aspart and human insulin.¹

¹ Becker KL: Principles and Practice of Endocrinology and Metabolism, third edition 2001. and Lindholm A et. al. Immune responses to insulin aspart. Diabetes Care 2002; 25: 876-82.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>